SK Capital invests in Spectrum Vascular

Founded in 2023, Spectrum Vascular acquired the vascular access businesses of Cook Medical in 2023 and AngioDynamics in 2024

Abbott launches intravascular lithotripsy trial aimed at clearing coronary arteries

Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound pressure waves to treat arterial calcium blockages

Bristol Myers Squibb showcases cardiovascular portfolio at AHA Scientific Sessions 2024

Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS

Finerenone showed statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure

Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%

Bristol Myers Squibb to present data across cardiovascular portfolio at ECS 2024

New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases

Finerenone meets primary endpoint in Phase III FINEARTS-HF cardiovascular study

Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy

Sanofi India inks distribution partnership with Emcure to expand reach of its cardiovascular brands

Lupin launches ‘Jeet’ to raise awareness of cardiovascular disease among patients

Jeet will be a trusted partner in cardiovascular care

Lupin Digital Health and American College of Cardiology collaborate for in-home cardiovascular care in India

Riparian Pharmaceuticals inks license and research agreement with Pfizer for cardiovascular programs

Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics